Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0002144542-26-000003
Filing Date
2026-08-07
Accepted
2026-08-07 16:33:42
Documents
2
Period of Report
2026-08-01

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1652
2 EX-24 vktx-ex24.htm EX-24 10305
  Complete submission text file 0002144542-26-000003.txt   13376
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 500 SAN DIEGO CA
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 500 SAN DIEGO CA 858-704-4660
Viking Therapeutics, Inc. (Issuer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 9920 PACIFIC HEIGHTS BLVD SUITE 500 SAN DIEGO CA 92121
Business Address
Kelly-Gemmell Dorothy Elizabeth (Reporting) CIK: 0002144542 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37355 | Film No.: 261254834